Antimicrobial Susceptibility of Pseudomonas aeruginosa to Ceftazidime-Avibactam, Ceftolozane-Tazobactam, Piperacillin-Tazobactam, and Meropenem Stratified by U.S. Census Divisions: Results from the 2017 INFORM Program.

Related Articles

Antimicrobial Susceptibility of Pseudomonas aeruginosa to Ceftazidime-Avibactam, Ceftolozane-Tazobactam, Piperacillin-Tazobactam, and Meropenem Stratified by U.S. Census Divisions: Results from the 2017 INFORM Program.

Antimicrob Agents Chemother. 2018 Sep 17;:

Authors: Sader HS, Flamm RK, Carvalhaes CG, Castanheira M

Abstract
P. aeruginosa isolates (n = 1,909) were collected from 70 United Sates medical centers and susceptibility tested by broth microdilution method. Ceftazidime-avibactam (MIC50/90, 2/8 mg/liter) and ceftolozane-tazobactam (MIC50/90, 0.5/2 mg/liter) were the most active (highest susceptibility rates) compounds after colistin, with national susceptibility rates of 96.9% and 97.5%, respectively. Overall, piperacillin-tazobactam (MIC50/90, 4/128 mg/liter) and meropenem (MIC50/90, 0.5/16 mg/liter) were active against 77.5% and 76.0%, respectively. Susceptibility variations across census divisions were documented for many antimicrobials.

PMID: 30224535 [PubMed - as supplied by publisher]